This exploratory analysis suggested a trend toward greater efficacy and improved safety of LTP with lanadelumab 150 mg Q2W versus LTP with C1-INH(IV) 1000 IU and 500 IU in pediatric patients with HAE. The gene discussed is SERPING1; the disease is hereditary angioedema.